title: TG-4010 Transgene.
abstract: Transgene is developing TG-4010, a second-generation modified vaccinia virus Ankara encoding MUC1 and interleukin-2 for the potential treatment of a variety of cancer types. Phase II trials are underway for non-small-cell lung cancer, metastatic renal cancer and prostate cancer.
authors.affiliation: Department of Surgery, Columbia University, 177 Fort Washington Avenue, New York, NY 10032, USA.
authors.forename: Seth
authors.initials: S
authors.lastname: Cohen
authors.forename: Howard L
authors.initials: HL
authors.lastname: Kaufman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004345:Drug Industry / Q000379:methods*; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D014616:Vaccinia virus / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D015507:Drugs, Investigational